Lutterbach tested positive for the presence of 3a-Hydroxy-2a-methyl-5a-androstan-17-one, a metabolite of drostanolone, an anabolic steroid that is prohibited at all times, in a urine sample collected out of competition by Drug Free Sport International (DFSI), the biological sample collection and shipping agency of the UFC’s ADP, on June 8, 2024. After signing a bout agreement in late May to compete on the June 22, 2024, UFC card in Saudi Arabia, DFSI was able to promptly collect a sample from Lutterbach in Dusseldorf, Germany and request expedited laboratory analysis to have the sample results returned before the June 22nd card.
Statement On Joilton Lutterbach
